Edward Tenthoff
Stock Analyst at Piper Sandler
(3.14)
# 1,182
Out of 4,667 analysts
188
Total ratings
40.76%
Success rate
2.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $247.65 | +19.53% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $36.55 | +88.78% | 12 | Nov 18, 2024 | |
| OMGA Omega Therapeutics | Maintains: Overweight | $9 → $4 | $0.78 | +410.20% | 5 | Nov 15, 2024 | |
| KRON Kronos Bio | Downgrades: Neutral | $6 → $1 | $0.85 | +17.65% | 7 | Nov 14, 2024 | |
| TPST Tempest Therapeutics | Maintains: Overweight | $8 → $5 | $0.89 | +464.27% | 4 | Nov 13, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $18 | $5.46 | +229.97% | 1 | Nov 5, 2024 | |
| CAPR Capricor Therapeutics | Initiates: Overweight | $35 | $18.86 | +85.58% | 1 | Oct 21, 2024 | |
| STRO Sutro Biopharma | Reiterates: Overweight | $11 | $2.64 | +316.67% | 6 | Oct 11, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $62 | $18.53 | +234.59% | 10 | Oct 8, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Overweight | $53 | $29.63 | +78.90% | 5 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.41 | +353.51% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.58 | +90.48% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $5 | $0.28 | +1,684.44% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $1.09 | +176.50% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $11 | $10.12 | +8.75% | 3 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $8.34 | +91.85% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $46.98 | +123.50% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $40.00 | +125.00% | 3 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $12 | $1.26 | +852.38% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $2.17 | +177.14% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 | $0.28 | +1,694.04% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.87 | +168.08% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $37 → $24 | $23.66 | +1.44% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $2.96 | +406.76% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $43.64 | +28.34% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.69 | +271.75% | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $22.50 | +144.44% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $1.06 | +2,838.39% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.33 | +811.58% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $1.32 | +354.92% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.82 | +991.31% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $21.70 | +102.81% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $20.38 | +81.55% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3,036 → $880 | $0.28 | +311,956.74% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $585.05 | -39.49% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.44 | +9,243.85% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $448.13 | -27.92% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $34.75 | +3.61% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $3.13 | +698.72% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.58 | +25,851.56% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $9.58 | +453.52% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $1.19 | +115,846.90% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $741.13 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $247.65
Upside: +19.53%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $36.55
Upside: +88.78%
Omega Therapeutics
Nov 15, 2024
Maintains: Overweight
Price Target: $9 → $4
Current: $0.78
Upside: +410.20%
Kronos Bio
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.85
Upside: +17.65%
Tempest Therapeutics
Nov 13, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $0.89
Upside: +464.27%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $5.46
Upside: +229.97%
Capricor Therapeutics
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $18.86
Upside: +85.58%
Sutro Biopharma
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.64
Upside: +316.67%
Arrowhead Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $62
Current: $18.53
Upside: +234.59%
Dyne Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $53
Current: $29.63
Upside: +78.90%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.41
Upside: +353.51%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.58
Upside: +90.48%
Aug 13, 2024
Reiterates: Overweight
Price Target: $13 → $5
Current: $0.28
Upside: +1,684.44%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $1.09
Upside: +176.50%
Jul 23, 2024
Upgrades: Overweight
Price Target: $4 → $11
Current: $10.12
Upside: +8.75%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $8.34
Upside: +91.85%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $46.98
Upside: +123.50%
Jun 17, 2024
Reiterates: Overweight
Price Target: $90
Current: $40.00
Upside: +125.00%
Jun 17, 2024
Maintains: Overweight
Price Target: $9 → $12
Current: $1.26
Upside: +852.38%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $2.17
Upside: +177.14%
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $0.28
Upside: +1,694.04%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.87
Upside: +168.08%
Feb 28, 2024
Downgrades: Neutral
Price Target: $37 → $24
Current: $23.66
Upside: +1.44%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $2.96
Upside: +406.76%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $43.64
Upside: +28.34%
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $2.69
Upside: +271.75%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $22.50
Upside: +144.44%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $1.06
Upside: +2,838.39%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.33
Upside: +811.58%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $1.32
Upside: +354.92%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.82
Upside: +991.31%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $21.70
Upside: +102.81%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $20.38
Upside: +81.55%
May 13, 2022
Maintains: Overweight
Price Target: $3,036 → $880
Current: $0.28
Upside: +311,956.74%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $585.05
Upside: -39.49%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.44
Upside: +9,243.85%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $448.13
Upside: -27.92%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $34.75
Upside: +3.61%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $3.13
Upside: +698.72%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.58
Upside: +25,851.56%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $9.58
Upside: +453.52%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $1.19
Upside: +115,846.90%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $741.13
Upside: -